Synthesis of triazolotriazine derivatives as c-Met inhibitors

被引:6
|
作者
Guo, Yuting [1 ,3 ]
Peng, Xia [2 ]
Ji, Yinchun [2 ]
Zhang, Yitong [2 ,3 ]
Ding, Jian [2 ,3 ]
Zhan, Zhengsheng [1 ]
Ai, Jing [2 ,3 ]
Duan, Wenhu [1 ,3 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China
[3] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
Receptor tyrosine kinase; c-Met; Triazolotriazine; SAR; Cellular potency; GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR; HIGHLY POTENT; DISCOVERY; IDENTIFICATION; PROTOONCOGENE; CABOZANTINIB; METASTASIS; VOLITINIB; PATHWAY;
D O I
10.1007/s11030-020-10067-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Receptor tyrosine kinase c-Met is an important antitumor drug target. Triazolotriazine analogues2-10were prepared efficiently and evaluated the enzymatic and cellular c-Met activities. Brief structure-activity relationships of triazolotriazine core and CF2-quinoline part were investigated, leading to the discovery of compound8with nanomolar enzymatic c-Met activity, and subnanomolar MKN45 and EBC-1 cellular potencies. The proposed binding model of 8 and c-Met unraveled that two canonical hydrogen bonds and a pi-pi stacking interaction formed between the inhibitor and the ATP binding site of c-Met kinase domain, which accounted for its potent c-Met activities. [GRAPHICS] .
引用
收藏
页码:839 / 846
页数:8
相关论文
共 50 条
  • [31] Safety and Tolerability of c-MET Inhibitors in Cancer
    Puccini, Alberto
    Marin-Ramos, Nagore I.
    Bergamo, Francesca
    Schirripa, Marta
    Lonardi, Sara
    Lenz, Heinz-Josef
    Loupakis, Fotios
    Battaglin, Francesca
    DRUG SAFETY, 2019, 42 (02) : 211 - 233
  • [32] Safety and Tolerability of c-MET Inhibitors in Cancer
    Alberto Puccini
    Nagore I. Marín-Ramos
    Francesca Bergamo
    Marta Schirripa
    Sara Lonardi
    Heinz-Josef Lenz
    Fotios Loupakis
    Francesca Battaglin
    Drug Safety, 2019, 42 : 211 - 233
  • [33] c-MET Inhibitors in the Treatment of Lung Cancer
    Joanna Goździk-Spychalska
    Katarzyna Szyszka-Barth
    Łukasz Spychalski
    Katarzyna Ramlau
    Jerzy Wójtowicz
    Halina Batura-Gabryel
    Rodryg Ramlau
    Current Treatment Options in Oncology, 2014, 15 : 670 - 682
  • [34] The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
    Varkaris, Andreas
    Corn, Paul G.
    Gaur, Sanchaika
    Dayyani, Farshid
    Logothetis, Christopher J.
    Gallick, Gary E.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (12) : 1677 - 1684
  • [35] Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors
    Ryu, Jae Wook
    Han, Sun-Young
    Yun, Jeong In
    Choi, Sang-Un
    Jung, Heejung
    Du Ha, Jae
    Cho, Sung Yun
    Lee, Chong Ock
    Kang, Nam Sook
    Koh, Jong Sung
    Kim, Hyoung Rae
    Lee, Jongkook
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 7185 - 7188
  • [36] Indazoles as potential c-met inhibitors: Design, synthesis and molecular docking studies
    Ye, Lianbao
    Ou, Xiaomin
    Tian, Yuanxin
    Yu, Bangwei
    Luo, Yan
    Feng, Binghong
    Lin, Hansen
    Zhang, Jiajie
    Wu, Shuguang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 65 : 112 - 118
  • [37] Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
    Dong, Yuhong
    Hu, Hao
    Sun, Yuwei
    Qin, Mingze
    Gong, Ping
    Hou, Yunlei
    Zhao, Yanfang
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (23)
  • [38] Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer
    Wang, Zuoyang
    Shi, Zhichao
    Yang, Shiqi
    Niu, Zizhou
    Shu, Kaifei
    Chen, Linbo
    Zhi, Cailian
    Liu, Funian
    Huang, Wenjun
    Fan, Tingting
    Jiang, Yuyang
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (09): : 1516 - 1525
  • [39] Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors
    Li, Chunpu
    Ai, Jing
    Zhang, Dengyou
    Peng, Xia
    Chen, Xi
    Gao, Zhiwei
    Su, Yi
    Zhu, Wei
    Ji, Yinchun
    Chen, Xiaoyan
    Geng, Meiyu
    Liu, Hong
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05): : 507 - 512
  • [40] Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR
    Hu, Jinhui
    Chen, Li
    Lu, Zhonghui
    Yao, Han
    Hu, Yunfei
    Feng, Luanqi
    Pang, Yanqing
    Wu, Jia-Qiang
    Yu, Zhiling
    Chen, Wen-Hua
    MOLECULES, 2023, 28 (03):